A new trading day began on Friday, with Cognition Therapeutics Inc (NASDAQ: CGTX) stock price down -3.86% from the previous day of trading, before settling in for the closing price of $0.25. CGTX’s price has ranged from $0.22 to $2.54 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 52.62%. With a float of $50.25 million, this company’s outstanding shares have now reached $61.97 million.
Let’s determine the extent of company efficiency that accounts for 28 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cognition Therapeutics Inc (CGTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cognition Therapeutics Inc is 18.94%, while institutional ownership is 9.13%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares.
Cognition Therapeutics Inc (CGTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.88% during the next five years compared to -16.44% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Here are Cognition Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.73, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Looking closely at Cognition Therapeutics Inc (NASDAQ: CGTX), its last 5-days average volume was 1.05 million, which is a drop from its year-to-date volume of 1.28 million. As of the previous 9 days, the stock’s Stochastic %D was 18.37%. Additionally, its Average True Range was 0.03.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 2.47%, which indicates a significant decrease from 14.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.96% in the past 14 days, which was higher than the 83.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3700, while its 200-day Moving Average is $0.5141. However, in the short run, Cognition Therapeutics Inc’s stock first resistance to watch stands at $0.2504. Second resistance stands at $0.2619. The third major resistance level sits at $0.2694. If the price goes on to break the first support level at $0.2314, it is likely to go to the next support level at $0.2239. Should the price break the second support level, the third support level stands at $0.2124.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
With a market capitalization of 14.82 million, the company has a total of 61,993K Shares Outstanding. Currently, annual sales are 0 K while annual income is -33,970 K. The company’s previous quarter sales were 0 K while its latest quarter income was -8,480 K.
